Concert Pharmaceuticals - CTP-656 - Ownership and Business Overview

Life ScienceCompany

Concert Pharmaceuticals - CTP-656 Ownership

Who owns Concert Pharmaceuticals - CTP-656?

Concert Pharmaceuticals - CTP-656 is owned by Vertex Pharmaceuticals. It was acquired on March 6, 2017.

Concert Pharmaceuticals - CTP-656 Business Overview

Where is Concert Pharmaceuticals - CTP-656 headquartered?

Concert Pharmaceuticals - CTP-656 is headquartered in Lexington, Massachusetts.

What sector is Concert Pharmaceuticals - CTP-656 in?

Concert Pharmaceuticals - CTP-656 is a life science company.

Life Science M&A Summary in 2017

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2017. The largest life science acquisition in 2017 was Actelion - which was acquired by Johnson & Johnson for $30.0B.

Join Mergr to view all 248 acquisitions of life science companies in 2017, including 23 acquisitions by private equity firms, and 225 by strategics.

Concert Pharmaceuticals, Inc. - CTP-656

Lexington, Massachusetts 02421
United States,

Concert Pharmaceuticals, Inc. - CTP-656 was developed by Concert through the application of deuterium chemistry to modify Vertex’s CFTR potentiator, ivacaftor. Ivacaftor was discovered by Vertex scientists and is approved in the U.S., Europe, Canada and Australia for people with CF who have specific mutations in the CFTR gene. CTP-656 has the potential to play a key role in future once-daily combination regimens to treat CF. Concert is currently conducting a Phase 2 study of CTP-656 in people with CF who have gating mutations. As part of the agreement, Vertex will acquire rights to all of Concert’s other CF research and preclinical programs.


 Subscribe to unlock this and 206,067
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 201K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 79K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.